Source: Virtual Congress 2021 – Screening, diagnosis, management and prognosis of lung cancer



Rating:

Share or cite this content

Citations should be made in the following way:
J. Nunes Caldeira Marinho Matos (Coimbra, Portugal), S. Rodrigues Sousa (Coimbra, Portugal), A. Figueiredo (Coimbra, Portugal), A. Pego (Coimbra, Portugal), F. Barata (Coimbra, Portugal). Impact of PD-L1 expression levels on the response to pembrolizumab in metastatic non-small cell lung cancer>. 2189

Member's Comments

No comment yet.

Related content which might interest you: Role of EBUS-TBNA in the study of PD-L1 expression in patients with non-small cell lung cancer (NSCLC) Source: Virtual Congress 2020 – Endobronchial ultrasound: from rookie to pro Year: 2020 Evaluate soluble PD-L1 in plasma in advanced stage non-small cell lung cancer patients Source: Virtual Congress 2020 – Biological mechanisms of lung cancer Year: 2020 Importance of clusterin expression at tissue level for the prognosis of non-small cells lung cancer Source: Annual Congress 2009 - Lung cancer biology Year: 2009 p-53 and HER2/neu expression in relation to chemotherapy response in patients with non-small cell lung cancer Source: Annual Congress 2007 - Novel genetic markers in pathology Year: 2007 Survivin expression in non-small cell lung cancer Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases Year: 2010 Expression of ERCC1 in normal and tumor tissues in non-small cell lung cancer Source: Annual Congress 2007 - Biology of thoracic malignancies Year: 2007 XAGE-1b and p53: Potential targets for immunotherapy of non-small cell lung cancer (NSCLC) Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 Differential cytokine expression in non-small cell lung carcinomas Source: Eur Respir J 2007; 30: Suppl. 51, 512s Year: 2007 Prognostic value of ERCC1 expression in advanced non-small cell lung cancer (NSCLC) Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012 The value of CD44 and MMP-2 expression in non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 77s Year: 2004 Expression of βig-h3 as a marker of local tumor invasion in non-small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 770s Year: 2006 Expression of Her-2/neu and Bcl-2 in patients with non-small cell lung cancer Source: International Congress 2017 – Gene signatures in bronchial diseases Year: 2017 Her/2 neu and p53 expression in patients with non-small cell lung cancer predict shortened survival Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010 Choice of endogenous control for gene expression in nonsmall cell lung cancer Source: Eur Respir J 2005; 26: 1002-1008 Year: 2005 Characterization of patients with non-small cell lung cancer (NSCLC) relative to its EGFR mutational status Source: Annual Congress 2011 - Epidemiology of lung cancer and screening Year: 2011 Role of chemokines in resectable non-small cell lung cancer (NSCLC) Source: International Congress 2019 – Biology and prognosis of lung cancer Year: 2019 Prognostic value of p21 protein expression in non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 674s Year: 2004 24h-blood profile gene expression biomarkers of the response to bevacizumab-erlotinib (BE) in advanced non-squamous non-small cell lung cancer (NSCLC) Source: International Congress 2016 – Therapeutic trials in lung cancer Year: 2016 p53 mutations do not predict response to paclitaxel in metastatic non-small cell lung carcinoma Source: Annual Congress 2009 - Lung cancer biology Year: 2009 Influence of overexpression of coagulantic and fibrolytic components in tumor tissues on the prognosis of non-small cell lung cancer Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology Year: 2007